INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL
PACIFIC2/D933KC00001
Phase 3 small_molecule active
Quick answer
INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL for Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active